$2.34 Billion Viral Vector and Plasmid DNA Manufacturing Markets, 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Viral Vector and Plasmid DNA Manufacturing Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering

The viral vector and plasmid DNA manufacturing market is projected to reach USD 2,344.29 million by 2027, registering a CAGR of 23.38 % during the forecast period (2022-2027).

The COVID-19 outbreak is expected to positively impact the viral vector and plasmid DNA manufacturing market. Several COVID-19 vaccine candidates entering clinical trials also include viral vector vaccines. These vaccines are likely to be among the COVID-19 vaccines authorized for use worldwide.

Many of them have also received or are in the final stages of receiving approval. In January 2021, Johnson & Johnson announced favorable efficacy and safety data from its Phase 3 ENSEMBLE clinical trial using its AdVac vaccine platform for COVID-19. Its single-dose COVID-19 vaccine, currently under development at its Janssen Pharmaceutical Companies, met all preconditions and targets.

The AdVac viral vector technology could provide a potent and long-lasting humoral and cellular immune response to the body. Another viral vector-based vaccine, which has received several approvals, is the Oxford-AstraZeneca COVID-19 vaccine. The vaccine was first discovered in November 2020 and has since been mass-produced to vaccinate people.

The COVID-19 viral vector vaccines are under development worldwide using non-replicating viral vectors. The immune response of these vaccines follows a similar pattern, i.e., it includes antibody-producing B cells and T cells, which seek out and destroy infected cells in the body, providing long-lasting immunity. Further research and increased investment in this field are expected to positively affect vaccine development.

Demand for plasmid DNA is growing steadily due to growth in gene therapy development. pDNA is a prerequisite for producing AAV (adeno-associated virus), lentivirus, and other viral vector platforms. There is also an increase in several genetic disorders and numerous life-threatening disorders, especially heart diseases, AIDS, cystic fibrosis, and age-related disorders.

For instance, as per the Centers for Disease Control and Prevention, 2021, hypertension, or high blood pressure, is a leading risk factor for cardiovascular disease and causes an estimated 10 million deaths worldwide each year. These statistics represent 35% of global deaths.

Gene therapy with viral vectors provides a complete cure to patients suffering from genetic disorders and other life-threatening disorders rather than ease symptoms with other treatments. Several clinical studies are being conducted on viral vectors and plasmid DNA manufacturing, emphasizing the potential of gene therapy to address important medical needs.

Several players, including pharmaceutical companies, contract manufacturing organizations, research institutes, and non-profit organizations, are playing a critical role in the development and production of these vectors. In April 2021, ViroCell Biologics, the UK clinical trial-focused viral vector manufacturer, launched its viral vectors. Through this launch, the company will supply viral vectors and gene-modified cells to academic and corporate clients for translational cell and gene therapies going into clinical trials.

Key Market Trends

By Application, Cancer Segment is Expected to Register Robust Growth.

The upsurge in the global incidence of cancer and modern healthcare facilities are acting as major drivers for the segment growth. According to GLOBOCAN 2020, there were 1,929,2789 new cancer cases in 2020, and it is projected to increase to 28,887,940 cases by 2040.. Additionally, there are also many gene therapy strategies that have been developed to treat a wide range of cancers, including suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines.

According to a 2019 research article ‘Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells’, oncolytic virotherapy represents an emerging development in anticancer therapy. Although it has been tested against a variety of cancers, including breast cancer, the efficacy of oncolytic viral vectors delivered as monotherapy is limited. Oncolytic virotherapy is a promising treatment that selectively targets and destroys cancer tissues with minimal damage to normal cells.

Currently, there are numerous Phase I and Phase II clinical trials related to viral vectors for the treatment of various types of cancers, such as brain, skin, liver, colon, breast, and kidney, among others, which are being conducted in academic centers and biotechnology companies.

Moreover, gene therapy based on viral vectors has established steady progress in the area of cancers recently. There is a mass of viral vectors that have been engineered for both preventive and therapeutic applications. Market players are also adopting various market strategies in developing novel products.

Competitive Landscape

The market is still in the nascent stage. Hence, increasing focus is mainly on the development of innovative products. Key market players include Cobra Biologics, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., and Thermo Fisher Scientific.

Market Dynamics

Market Drivers

• Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
• Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development
• Potential Applications in Novel Drug Delivery Approaches

Market Restraints

• High Cost of Gene Therapies
• Challenges in Viral Vector Manufacturing Capacity

Company Profiles

• Oxford Biomedica
• Cognate BioServices Inc. (Cobra Biologics)
• Cell and Gene Therapy Catapult
• FinVector Vision Therapies
• Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• MassBiologics
• SIRION Biotech
• Merck KGaA Inc.
• Thermo Fisher Scientific
• Uniqure NV
• Catalent Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ag1tr0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900